Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries

Table 4 Endometrial cancer mortality in relation to age at diagnosis, FIGO stage and morphology of endometrial cancer

	Patients	Endometrial cancer mortality
	N	Deaths	HR	95% CI
Age at diagnosis of endometrial cancer^a
< 55	190	14	1.00	baseline
55 to 64	469	51	1.57	0.87, 2.84
65 to 74	653	87	2.13	1.21, 3.75
75 to 84	445	92	3.65	2.08, 6.43
85 and over	118	33	5.69	3.03, 10.7
Heterogeneity (4 d.f.)			P < 0.0001
Trend (1 d.f.)			P < 0.0001
FIGO stage^b
I	1016	64	1.00	baseline
II	132	26	3.34	2.11, 5.28
III/IV	140	67	13.1	9.25, 18.6
Unknown	587	120	2.92	2.06, 4.14
Heterogeneity (3 d.f.)			P < 0.0001
Morphology^c
Endometrioid^d	1580	162	1.00	baseline
Serous or clear cell^e	108	32	2.25	1.51, 3.37
Carcinosarcoma^f	108	54	5.41	3.92, 7.45
Sarcoma^g	54	20	3.93	2.42, 6.38
Unknown	25	9	4.11	2.06, 8.14
Heterogeneity (4 d.f.)			P < 0.0001
All non-endometrioid^h	270	106	3.75	2.88, 4.87
Morphology by tamoxifen use^c
Tamoxifen users:
- non-endometrioid	190	79	3.32	2.06, 5.35
-endometrioid	929	105	1.00	baseline
Tamoxifen non-user
- non-endometrioid	80	27	3.88	2.86, 5.28
-endometrioid	651	57	1.00	baseline
Heterogeneity interaction^h (1 d.f.)			P = 0.57
Morphology unknown:	25	9

^aAdjusted for time since diagnosis of endometrial cancer, study, calendar period, FIGO stage;
^badjusted for time since diagnosis of endometrial cancer, study, calendar period, attained age;
^cadjusted for time since diagnosis of endometrial cancer, study, calendar period, FIGO stage, attained age;
^d endometrial adenocarcinoma, mixed cell adenocarcinoma, papillary endometrial adenocarcinoma;
^eserous adenocarcinoma, clear cell adenocarcinoma; ^fcarcinosarcoma, Mullerian mesodermal mixed tumors; ^gsarcoma, endometrial stromal adenocarcinoma, leiomyosarcoma; ^hExcludes those where morphology was unknown. CI, confidence interval; FIGO, International Federation of Gynaecology and Obstetrics; HR, hazard ratio; N, number.

ISSN: 1465-542X